Kindred Biosciences, Inc. (KIN) Expanded Agreement with Vaxart To Gear Up Manufacturing Of COVID-19 and Other Vaccine Candidates


Kindred Biosciences, Inc. (KIN) this week came expanding an agreement with Vaxart, Inc. for the manufacturing of Vaxart’s oral vaccine for COVID-19 as well as other vaccine candidates.

The biopharmaceutical company developing novel biologics will be performing manufacturing services through its wholly owned subsidiary Centaur Biopharmaceutical Services (Centaur), which is a provider of full service contract development and manufacturing services.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


KindredBio showed excitement in expanding its collaboration with Vaxart for its readiness into the clinical trials of its novel COVID-19 vaccine candidate, said KindredBio’s Chief Executive Officer, Richard Chin, M.D. The agreement to expand collaboration will further strengthen the company as preferred partner for contract manufacturing. This will also help the company in supporting the progress toward a long-term goal that involves a series of late stage assets.

As per the agreed terms, company’s California plant will scale up the material for clinical trial of COVID-19 into mid-size bioreactors. Kansas plant of the company will be manufacturing at 2000L scale in its single use bioreactors.

Vaxart’s Chief Executive Officer, Andrei Floroiu commented that KindredBio’s up to the mark capabilities in viral vector manufacturing made his company to enter into an agreement with KindredBio for commercial scale bulk manufacturing. The move will be step forward to further advance its oral tablet vaccine candidate for COVID-19. It will also be helpful in accelerating Vaxart’s global mass vaccination campaign.

Vixart entered into this agreement to gear up its manufacturing network ahead of a potential roll-out of its experimental COVID-19 vaccine into the clinic. Vaxart’s candidate for the COVID-19 differs from similar candidates by other companies as the vaccine is in form of tablet rather than the more common method of an injection. That oral form of the vaccine is not only an easier and convenient way of storing and shipping it but could also be providing a more pleasant patient experience.